Literature DB >> 31008694

Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Molly Doernberg1, Noa Krawczyk2,3, Deborah Agus2,3, Michael Fingerhood2,4.   

Abstract

Buprenorphine is considered one of the most effective treatments for opioid use disorder and significantly reduces risk of overdose death. However, concerns about its diversion and misuse have often taken center stage in public discourse and in the design of practices and policies regarding its use. This has been to the detriment of many vulnerable patient populations, especially those involved in the criminal justice system. Policies that restrict access to buprenorphine in criminal justice and other settings due to concerns of diversion do not accurately reflect the relative risks and safety profile associated with it, creating unnecessary barriers that drive an illicit market of this much-needed medication. Although proper regulation of all controlled medications should be a priority, in most instances the benefits of buprenorphine highly outweigh its risks. In the midst of a national crisis, efforts should be focused on expanding, and not restricting, access to this lifesaving treatment.

Entities:  

Keywords:  Addiction; buprenorphine; criminal justice; diversion; opioid; substance use

Year:  2019        PMID: 31008694      PMCID: PMC6800751          DOI: 10.1080/08897077.2019.1572052

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  57 in total

1.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

2.  Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Authors:  Michelle R Lofwall; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2012-06-15       Impact factor: 4.492

3.  Post-marketing surveillance of methadone and buprenorphine in the United States.

Authors:  Nabarun Dasgupta; Elise J Bailey; Theodore Cicero; James Inciardi; Mark Parrino; Andrew Rosenblum; Richard C Dart
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

4.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.

Authors:  V Tomasino; A J Swanson; J Nolan; H I Shuman
Journal:  Mt Sinai J Med       Date:  2001-01

Review 5.  Initial strategies for integrating buprenorphine into HIV care settings in the United States.

Authors:  Lynn E Sullivan; Robert D Bruce; David Haltiwanger; Gregory M Lucas; Lois Eldred; Ruth Finkelstein; David A Fiellin
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

6.  Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.

Authors:  Bennett Allen; Alex Harocopos
Journal:  J Subst Abuse Treat       Date:  2016-08-12

7.  Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Authors:  Harlan Matusow; Samuel L Dickman; Josiah D Rich; Chunki Fong; Dora M Dumont; Carolyn Hardin; Douglas Marlowe; Andrew Rosenblum
Journal:  J Subst Abuse Treat       Date:  2012-12-03

Review 8.  Treating substance use disorders in the criminal justice system.

Authors:  Steven Belenko; Matthew Hiller; Leah Hamilton
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

9.  Medication-assisted treatment for opioid dependence: making a difference in prisons.

Authors:  Anna Pecoraro; George E Woody
Journal:  F1000 Med Rep       Date:  2011-01-14

10.  Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.

Authors:  Torkel Richert; Björn Johnson
Journal:  Harm Reduct J       Date:  2015-02-18
View more
  11 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.

Authors:  Ashley Buchanan; Tianyu Sun; Jing Wu; Hilary Aroke; Jeffrey Bratberg; Josiah Rich; Stephen Kogut; Joseph Hogan
Journal:  Stat Med       Date:  2022-06-08       Impact factor: 2.497

3.  "You're Not Supposed to be on it Forever": Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids.

Authors:  Julia Dickson-Gomez; Antoinette Spector; Margaret Weeks; Carol Galletly; Madelyn McDonald; Helena Danielle Green Montaque
Journal:  Subst Abuse       Date:  2022-06-27

4.  Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.

Authors:  Elizabeth A Evans; Ekaterina Pivovarova; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann
Journal:  J Subst Abuse Treat       Date:  2022-02-23

5.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

6.  Designing and implementing an intervention for returning citizens living with substance use disorder: discovering the benefits of peer recovery coach involvement in pilot clinical trial decision-making.

Authors:  Grant Victor; Emily Sightes; Dennis P Watson; Bradley Ray; Katie Bailey; Lisa Robision; Gina Fears; Rhiannon Edwards; Michelle Salyers
Journal:  J Offender Rehabil       Date:  2021-01-11

7.  Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.

Authors:  Paxton Bach; Misha Bawa; Cameron Grant; M J Milloy; Kanna Hayashi
Journal:  Int J Drug Policy       Date:  2021-12-05

8.  Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths.

Authors:  Brandon Del Pozo; Lawrence S Krasner; Sarah F George
Journal:  J Law Med Ethics       Date:  2020-06       Impact factor: 1.604

9.  COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.

Authors:  Lauren Caton; Hannah Cheng; Hélène Chokron Garneau; Tammy Fisher; Briana Harris-Mills; Brian Hurley; Sandra Newman; Mark P McGovern
Journal:  J Gen Intern Med       Date:  2021-01-28       Impact factor: 5.128

10.  Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.

Authors:  Lila Flavin; Babak Tofighi; Noa Krawczyk; Daniel Schatz; Jennifer McNeely; Jenna L. Butner
Journal:  J Addict Med       Date:  2022 Jan-Feb 01       Impact factor: 4.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.